 |
|
|
| |
Sustained Virologic Response After ACH-3102 and Sofosbuvir Treatment for 8 or 6 Weeks: a Phase 2 "Proxy" Study
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Ed Gane1,2, Christian Schwabe1, Michael Mader3, Vithika Suri2, Mary Donohue3, Mingjun Huang3, James Hui3, Joanna Yang3, Heather Robison3, David Apelian3, Hetal Kocinsky3
Affiliations: 1Auckland Clinical Studies Ltd, Grafton, New Zealand; 2Auckland City Hospital, Auckland, New Zealand; 3Achillion Pharmaceuticals, New Haven, CT, USA
|
| |
|
|
|
|
|
